Two proxy advisory firms back Biogen Idec nominees for election on June 19

By Lisa Kerner

Charlotte, N.C., June 10 - Biogen Idec Inc. said that RiskMetrics Group/ISS Governance Services and Glass, Lewis & Co. recommended that its stockholders vote for all four of the company's director nominees for election to the board on June 19.

Stockholders are urged to use the white proxy card to vote for Cecil B. Pickett, Ph.D., Lynn Schenk, J.D., Phillip A. Sharp, Ph.D., and Stelios Papadopoulos, Ph.D., according to a Biogen Idec news release.

It was previously reported that Carl Icahn put forth a dissident slate of director nominees for election to Biogen Idec's board: Alexander J. Denner, Richard C. Mulligan and Anne B. Young.

Denner is managing director of entities controlled by Icahn that manage private investment funds.

Mulligan is Mallinckrodt Professor of Genetics at Harvard Medical School and director of the Harvard Gene Therapy Initiative.

Young is Julianne Dorn Professor of Neurology at Harvard Medical School and chief of neurology service at Massachusetts General Hospital.

Biogen Idec, in a prior statement, said it believes Icahn has consistently promoted a single-minded agenda to sell the Cambridge, Mass.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.